GEN Exclusives

More »

GEN News Highlights

More »
Jul 25, 2013

Studies Test Abilities of CRISPR-Cas9 Systems to Hit their Targets

  • As CRISPR/Cas comes of age, synthetic RNA-guided transcription factors are the stars of two independent studies published in Nature Methods today. 

    The first, from Duke University’s Charles Gersbach, Ph.D., and his colleagues present a Cas9-based transactivator targeted to DNA sequences by guide RNA molecules. In their paper, Dr. Gersbach et al. show that coexpression of this transactivator plus combinations of guide RNAs in human cells “induced specific expression of endogenous target genes, demonstrating a simple and versatile approach for RNA-guided gene activation,” they write.

    Separately, J. Keith Joung, M.D., Ph.D., and his colleagues at Massachusetts General Hospital show that single or multiple short guide RNAs (gRNAs) can direct dCas9 fused to a VP64 transcriptional activation domain to increase expression of endogenous human genes. “This proof-of-principle work shows that [CRISPR]-Cas systems can target heterologous effector domains to endogenous sites in human cells,” Dr. Joung et al. write.

    CRISPR RNA-guided nuclease—or RGNs—are not without their potential pitfalls, however. In June, MGH’s Dr. Joung and colleagues reported having found that CRISPR-associated RGNs readily produce off-target alterations

    “RNA-guided gene activation by CRISPRCas9-based transcription factors” and “CRISPR RNA-guided activation of endogenous human genes” appeared online in Nature Methods July 25.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »